ACHILLION PHARMACEUTICALS
Summary
Achillion is a clinical-stage biopharmaceutical company focused on the development of oral small molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases.
Deals Overview
Total Deals1
Valued Deals1
Total Value£ 733 M
Avg. Deal Size£ 733 M
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
